US generic drug tariffs could reach 200%

The US administration has outlined a phased tariff programme for imported generic medicines that would preserve zero-duty treatment for two years before imposing rates of 100% and eventually 200%.

The White House intends the sequence to begin on 1 August, after which qualifying generic medicines would remain tariff-free for the initial two-year period. Duties would then rise to 100% for one year before doubling again.

The policy is designed to encourage pharmaceutical manufacturers to establish or expand US production during the zero-duty window. Detailed implementing rules, product definitions, exemptions, and the legal mechanism for imposing the tariff have not yet been set out.

Generic medicines present unusually difficult reshoring economics because prices and margins are substantially lower than those of patented products. Competition between several approved suppliers can leave little commercial capacity to fund a new plant or absorb a major tariff.

Production cannot be transferred merely by moving machinery. A manufacturer must secure a suitable facility, qualify equipment and utilities, validate the process, approve raw-material suppliers, establish analytical methods, produce stability data, and obtain regulatory clearance before commercial batches can enter distribution.

Even when final tablet, capsule, or injectable production moves to the US, active pharmaceutical ingredients, excipients, primary packaging, laboratory materials, and specialist equipment may remain internationally sourced. Tariff treatment will depend partly on how the final rules define origin and qualifying manufacture.

Two years leaves a narrow pharmaceutical transfer window

A two-year period is generous beside an immediate tariff but short against normal pharmaceutical capital and validation cycles. Acquiring an existing approved site may accelerate the process, although suitable capacity is scarce and product-specific approvals remain necessary after a change in ownership or location.

Manufacturers will first decide which medicines justify investment. High-volume products with stable demand may support domestic production, whereas low-volume or highly competitive lines could become commercially unattractive under either a tariff or an expensive transfer programme.

Some suppliers may withdraw rather than build new capacity, particularly where purchasers cannot guarantee volume or accept a higher unit price. Reduced participation would weaken redundancy in markets that already depend on a small number of approved manufacturers.

Buyer behaviour will shape the outcome because wholesalers, health systems, pharmacies, and public procurement organisations have historically used competition to drive generic prices lower. Contract models centred exclusively on lowest unit cost conflict with the expense of maintaining spare domestic capacity.

Longer purchasing commitments, volume guarantees, or price adjustments may be needed to support investment. Suppliers are also likely to seek explicit tariff pass-through clauses rather than carry an open-ended trade-policy risk within fixed-price contracts.

Inventory may rise before higher duties take effect, particularly for stable products with long shelf lives. Building stock would provide a temporary buffer but increase working capital, warehouse demand, expiry exposure, insurance, and the risk of an abrupt availability gap once the reserve is depleted.

Origin changes will also affect logistics qualification. Certified pharmaceutical networks, including the expanded GEODIS handling operation across Poland, depend on controlled processes for storage, transport, monitoring, security, and documentation; a new manufacturing source must be incorporated into equally robust lanes.

Ambient products, cold-chain medicines, controlled substances, and high-value injectables each impose different transport and storage requirements. Changing a production site can require packaging qualification, route validation, revised customs procedures, new release arrangements, and updated product-traceability records.

Shortage risk remains the central operational concern. A single plant interruption can remove a large share of supply where only two or three manufacturers remain active, while a tariff-induced withdrawal could produce the same effect without any physical production failure.

Domestic manufacture does not automatically create diversification. Several products may depend on one contract manufacturer, API plant, packaging supplier, testing laboratory, or sterilisation facility, concentrating risk inside the country rather than removing it.

Rules of origin will be especially complex where APIs, bulk product, packaging, labelling, testing, and final release occur in different jurisdictions. Importers need a clear test for determining tariff liability and sufficient time to amend supplier records and customs data.

The generic plan also sits alongside separate tariffs for patented pharmaceutical products, creating different treatment across product portfolios and supplier countries. Companies operating both branded and generic businesses will have to model several overlapping timetables and exemptions.

Investment decisions will begin before those details are complete because capacity, engineering contractors, equipment, and regulatory staff cannot be secured instantly. Waiting for absolute policy certainty may leave too little time to complete a transfer before the first 100% duty takes effect.

The proposed rates are high enough to alter sourcing decisions, although they do not guarantee a uniform shift into US production. Some products may be reshored, others could be routed through countries benefiting from future exemptions, and marginal lines may disappear from the market.

Implementation will ultimately determine whether the programme creates durable domestic capacity or adds cost and concentration to a fragile medicines supply chain. The zero-duty window offers time to act, but pharmaceutical validation moves far more slowly than tariff policy.